Somewhat Positive News Coverage Somewhat Unlikely to Affect Mirati Therapeutics (NASDAQ:MRTX) Stock Price

News articles about Mirati Therapeutics (NASDAQ:MRTX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.3878733655033 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Shares of Mirati Therapeutics stock traded up $0.40 on Wednesday, hitting $28.10. The company had a trading volume of 423,843 shares, compared to its average volume of 442,694. The company has a market cap of $827.69, a PE ratio of -10.11 and a beta of 2.15. Mirati Therapeutics has a 1 year low of $2.70 and a 1 year high of $37.62.

Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Thursday, March 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.06). equities analysts expect that Mirati Therapeutics will post -2.53 EPS for the current fiscal year.

MRTX has been the topic of a number of recent analyst reports. ValuEngine raised Mirati Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. BidaskClub downgraded Mirati Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. Zacks Investment Research downgraded Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. HC Wainwright boosted their price objective on Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Monday, March 12th. Finally, Barclays began coverage on Mirati Therapeutics in a research note on Monday, March 12th. They set an “overweight” rating and a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $25.44.

In other Mirati Therapeutics news, CFO Jamie A. Donadio sold 12,100 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $35.00, for a total transaction of $423,500.00. Following the completion of the transaction, the chief financial officer now directly owns 12,100 shares of the company’s stock, valued at $423,500. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jamie A. Donadio sold 51,875 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $27.13, for a total value of $1,407,368.75. Following the transaction, the chief financial officer now directly owns 9,375 shares of the company’s stock, valued at $254,343.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 125,014 shares of company stock valued at $3,477,750. 5.10% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Mirati Therapeutics (NASDAQ:MRTX) Stock Price” was published by BBNS and is the property of of BBNS. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://baseballnewssource.com/2018/04/04/mirati-therapeutics-mrtx-receiving-somewhat-favorable-news-coverage-report-finds/2022084.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.